Alberto Tosetto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2451654/publications.pdf

Version: 2024-02-01

223 papers	21,542 citations	25423 59 h-index	10955 142 g-index
235 all docs	235 docs citations	235 times ranked	27511 citing authors

#	Article	IF	Citations
1	Association of Platelet Thromboxane Inhibition by Lowâ€Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia. Clinical Pharmacology and Therapeutics, 2022, 111, 939-949.	2.3	6
2	Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. Blood Advances, 2022, 6, 121-128.	2.5	7
3	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERSâ€IPS study. Journal of Thrombosis and Haemostasis, 2022, 20, 1106-1114.	1.9	5
4	Turoctocog alfa pegol (N8â€GP) in severe hemophilia A: Longâ€term safety and efficacy in previously treated patients of all ages in the pathfinder8 study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12674.	1.0	4
5	Outcomes of longâ€term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review. Haemophilia, 2022, 28, 373-387.	1.0	5
6	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Advances, 2022, 6, 3569-3578.	2.5	19
7	Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results. , 2022, 1, 38-44.		0
8	Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism. Internal and Emergency Medicine, 2021, 16, 359-368.	1.0	3
9	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Twoâ€year outcomes after the study closure. Journal of Thrombosis and Haemostasis, 2021, 19, 531-535.	1.9	40
10	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances, 2021, 5, 301-325.	2.5	152
11	Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Internal and Emergency Medicine, 2021, 16, 803-804.	1.0	116
12	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	1.9	19
13	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Advances, 2021, 5, 2987-3001.	2.5	11
14	von Willebrand disease: proposing definitions for future research. Blood Advances, 2021, 5, 565-569.	2.5	5
15	D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study. Internal and Emergency Medicine, 2020, 15, 453-462.	1.0	10
16	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	1.9	64
17	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	1.0	32
18	The value of bleeding scores in the assessment of patients presenting with bleeding of unknown cause: Bleeding assessment tools have still a place. European Journal of Internal Medicine, 2020, 78, 28-29.	1.0	1

#	Article	IF	Citations
19	Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia, 2020, 26, 937-945.	1.0	17
20	Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. BMJ Open, 2020, 10, e040449.	0.8	11
21	Anemone study: prevalence of risk factors for superficial vein thrombosis in a large Italian population of blood donors. Journal of Thrombosis and Thrombolysis, 2020, 50, 689-696.	1.0	1
22	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERSâ€IPS, an international and collaborative crossâ€sectional study. Journal of Thrombosis and Haemostasis, 2020, 18, 2145-2154.	1.9	20
23	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. Haematologica, 2020, 105, 1948-1956.	1.7	7
24	Managing anticoagulation in the COVID-19 era between lockdown and reopening phases. Internal and Emergency Medicine, 2020, 15, 783-786.	1.0	23
25	Efficacy and safety of rIX-FP in surgery: An update from a phase 3b extension study. Thrombosis Research, 2020, 193, 139-141.	0.8	3
26	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. Journal of Thrombosis and Thrombolysis, 2020, 50, 267-277.	1.0	54
27	Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials. Haemophilia, 2020, 26, 450-458.	1.0	11
28	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood, 2020, 136, 171-182.	0.6	65
29	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.3	22
30	Treatment With Efmoroctocog Alfa (EloctaÂ®) in Hemophilia: A Case Series. Clinical Management Issues, 2020, 14, .	0.3	0
31	Fixed doses of N8â€GP prophylaxis maintain moderateâ€toâ€mild factor VIII levels in the majority of patients with severe hemophilia A. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 542-554.	1.0	17
32	The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study. Internal and Emergency Medicine, 2019, 14, 1307-1315.	1.0	4
33	The American College of Chest Physicians score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolismâ€"Response. Journal of Thrombosis and Haemostasis, 2019, 17, 1182-1183.	1.9	0
34	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry. Journal of the American Heart Association, 2019, 8, e012596.	1.6	23
35	The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply. Journal of Thrombosis and Haemostasis, 2019, 17, 560-560.	1.9	1
36	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. HemaSphere, 2019, 3, e286.	1.2	43

#	Article	IF	Citations
37	Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfusion, 2019, 17, 171-180.	0.3	32
38	Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme. Journal of Thrombosis and Haemostasis, 2018, 16, 565-570.	1.9	23
39	The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply. Journal of Thrombosis and Haemostasis, 2018, 16, 2539-2540.	1.9	4
40	Phase 1, singleâ€dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Journal of Thrombosis and Haemostasis, 2018, 16, 1984-1993.	1.9	17
41	The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism. Journal of Thrombosis and Haemostasis, 2018, 16, 1994-2002.	1.9	32
42	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132, 1365-1371.	0.6	573
43	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine, 2018, 379, 1118-1127.	13.9	205
44	The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 2106-2110.	1.9	11
45	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer Journal, 2018, 8, 49.	2.8	30
46	Bleeding Patterns in Type I VWD in Effect of VWF Levels: An Individual Participant Data Meta-Analysis of Three Cohorts. Blood, 2018, 132, 1180-1180.	0.6	5
47	Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.. Blood, 2018, 132, 1184-1184.	0.6	0
48	Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project. Blood, 2018, 132, 2464-2464.	0.6	0
49	Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project). Blood, 2018, 132, 2465-2465.	0.6	2
50	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20Âyears ago. Internal and Emergency Medicine, 2017, 12, 1109-1119.	1.0	30
51	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica, 2017, 102, 1192-1203.	1.7	92
52	Scoring Systems for Estimating the Risk of Recurrent Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2017, 43, 493-499.	1.5	4
53	External validation of the DASH prediction rule: a retrospective cohort study. Journal of Thrombosis and Haemostasis, 2017, 15, 1963-1970.	1.9	55
54	European retrospective study of realâ€life haemophilia treatment. Haemophilia, 2017, 23, 105-114.	1.0	61

#	Article	IF	Citations
55	Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thrombosis and Haemostasis, 2017, 117, 252-261.	1.8	96
56	Bleeding Assessment Tools: Limits and Advantages for the Diagnosis and Prognosis of Inherited Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 2016, 42, 463-470.	1.5	9
57	Comparison between different <scp>D</scp>â€<scp>D</scp>imer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the <scp>DULCIS</scp> study. International Journal of Laboratory Hematology, 2016, 38, 42-49.	0.7	464
58	Duration of anticoagulation after isolated pulmonary embolism. European Respiratory Journal, 2016, 47, 1429-1435.	3.1	15
59	Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. Journal of Thrombosis and Haemostasis, 2015, 13, 1019-1027.	1.9	23
60	How I treat type 2 variant forms of von Willebrand disease. Blood, 2015, 125, 907-914.	0.6	46
61	Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study. Gastroenterology Research and Practice, 2015, 2015, 1-7.	0.7	11
62	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS ONE, 2015, 10, e0124719.	1.1	50
63	Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation. PLoS ONE, 2015, 10, e0144314.	1.1	16
64	Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. Journal of Thrombosis and Haemostasis, 2015, 13, 775-781.	1.9	57
65	Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease. PLoS ONE, 2015, 10, e0143913.	1.1	6
66	Laboratory tests during direct oral anticoagulant treatment?. Internal and Emergency Medicine, 2014, 9, 907-908.	1.0	1
67	Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatmentâ€related risk factors. Journal of Thrombosis and Haemostasis, 2014, 12, 1266-1273.	1.9	95
68	Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis. Thrombosis Research, 2014, 133, 1052-1055.	0.8	17
69	HDL-C, triglycerides and carotid IMT: A meta-analysis of 21,000 patients with automated edge detection IMT measurement. Atherosclerosis, 2014, 232, 65-71.	0.4	41
70	D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood, 2014, 124, 196-203.	0.6	160
71	Safety of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study. Blood, 2014, 124, 4276-4276.	0.6	0
72	Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. Journal of Clinical Epidemiology, 2013, 66, 415-425.	2.4	11

#	Article	IF	Citations
73	THE ROLE OF BLEEDING HISTORY AND CLINICAL MARKERS FOR THE CORRECT DIAGNOSIS OF VWD. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013051.	0.5	6
74	Magnetic resonance imaging and ultrasound evaluation of â€œhealthyâ€•joints in young subjects with severe haemophilia A. Haemophilia, 2013, 19, e167-73.	1.0	60
75	Bleeders, bleeding rates, and bleeding score. Journal of Thrombosis and Haemostasis, 2013, 11, 142-150.	1.9	57
76	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood, 2013, 121, 2596-2606.	0.6	179
77	Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM). Blood, 2013, 122, 581-581.	0.6	5
78	The Age-Specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: A Pooled Analysis. PLoS ONE, 2013, 8, e65174.	1.1	496
79	C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. New England Journal of Medicine, 2012, 367, 1310-1320.	13.9	909
80	Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. International Journal of Epidemiology, 2012, 41, 1419-1433.	0.9	230
81	Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. Blood, 2012, 120, 1327-1333.	0.6	99
82	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. Journal of Thrombosis and Haemostasis, 2012, 10, 1979-1987.	1.9	29
83	Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. Thrombosis and Haemostasis, 2012, 107, 477-484.	1.8	25
84	Different bleeding risk in type 2A and 2M von Willebrand disease: a 2â€year prospective study in 107 patients. Journal of Thrombosis and Haemostasis, 2012, 10, 632-638.	1.9	107
85	Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Journal of Thrombosis and Haemostasis, 2012, 10, 1019-1025.	1.9	353
86	Longâ€term outcomes of patients with cerebral vein thrombosis: a multicenter study. Journal of Thrombosis and Haemostasis, 2012, 10, 1297-1302.	1.9	129
87	Special indications for vitamin K antagonists: a review. Internal and Emergency Medicine, 2012, 7, 21-25.	1.0	5
88	Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment. Circulation, 2011, 124, 824-829.	1.6	188
89	0.10b Low-molecular-weight heparin for prevention of obstetric complications in carriers of factor V Leiden or PT-G20210A mutation. Thrombosis Research, 2011, 127, S128.	0.8	0
90	Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.. Thrombosis and Haemostasis, 2011, 106, 868-876.	1.8	158

#	Article	IF	Citations
91	Association of plasma fibrinogen, C-reactive protein and G-455>A polymorphism with early atherosclerosis in the VITA Project cohort. Thrombosis and Haemostasis, 2011, 105, 329-335.	1.8	12
92	Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thrombosis and Haemostasis, 2011, 105, 647-654.	1.8	44
93	A comparison between two semiâ€quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease. Haemophilia, 2011, 17, 165-166.	1.0	16
94	Is a reduced intensity treatment with Rituximab effective in acquired haemophilia A?. Haemophilia, 2011, 17, 817-818.	1.0	3
95	Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. Journal of Thrombosis and Haemostasis, 2011, 9, 1143-1148.	1.9	113
96	The unresolved challenge of subjects at intermediate cardiovascular risk. Internal and Emergency Medicine, 2011, 6, 297-298.	1.0	2
97	Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ: British Medical Journal, 2011, 342, d813-d813.	2.4	218
98	Carotid Plaque Morphology Improves Stroke Risk Prediction: Usefulness of a New Ultrasonographic Score. Cerebrovascular Diseases, 2011, 31, 300-304.	0.8	61
99	Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. Blood, 2011, 118, 544-544.	0.6	3
100	Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood, 2010, 115, 481-488.	0.6	134
101	Effect of prothrombin 19911 A>G polymorphism on the risk of cerebral sinusâ€venous thrombosis. European Journal of Neurology, 2010, 17, 1482-1485.	1.7	4
102	Sex, age and normal postâ€anticoagulation Dâ€dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. Journal of Thrombosis and Haemostasis, 2010, 8, 1933-1942.	1.9	35
103	Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. Journal of Thrombosis and Haemostasis, 2010, 8, 2078-2080.	1.9	9
104	ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. Journal of Thrombosis and Haemostasis, 2010, 8, 2063-2065.	1.9	607
105	Thrombophilic mutations and cardiovascular disease: the case is still open. Journal of Thrombosis and Haemostasis, 2010, 8, 2113-2115.	1.9	0
106	Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patientâ€level metaâ€analysis. Journal of Thrombosis and Haemostasis, 2010, 8, 2436-2442.	1.9	181
107	The impact of bleeding history, von Willebrand factor and PFAâ€“100^{Â®} on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDMâ€1VWD. British Journal of Haematology, 2010, 151, 245-251.	1.2	41
108	Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. Thrombosis and Haemostasis, 2010, 103, 1152-1160.	1.8	15

#	Article	IF	Citations
109	Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. International Journal of Epidemiology, 2010, 39, 1345-1359.	0.9	110
110	Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations. Haematologica, 2010, 95, 963-969.	1.7	53
111	Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thrombosis Research, 2010, 126, 227-231.	0.8	25
112	C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, The, 2010, 375, 132-140.	6.3	1,946
113	Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, The, 2010, 375, 2215-2222.	6.3	3,807
114	Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of<scp>d</scp>-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2010, 153, 523.	2.0	149
115	Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Hematology American Society of Hematology Education Program, 2009, 2009, 113-123.	0.9	17
116	Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA - Journal of the American Medical Association, 2009, 302, 412.	3.8	1,279
117	Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance. Journal of Thrombosis and Haemostasis, 2009, 7, 71-74.	1.9	40
118	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. American Journal of Hematology, 2009, 84, 584-588.	2.0	56
119	Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. Journal of Thrombosis and Thrombolysis, 2009, 28, 381-388.	1.0	32
120	Measures to assess the prognostic ability of the stratified Cox proportional hazards model. Statistics in Medicine, 2009, 28, 389-411.	0.8	41
121	Correcting for multivariate measurement error by regression calibration in metaâ€analyses of epidemiological studies. Statistics in Medicine, 2009, 28, 1067-1092.	0.8	59
122	Systematically missing confounders in individual participant data metaâ€analysis of observational cohort studies. Statistics in Medicine, 2009, 28, 1218-1237.	0.8	44
123	Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. Journal of Thrombosis and Haemostasis, 2009, 7, 1418-1421.	1.9	160
124	Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. Journal of Thrombosis and Haemostasis, 2009, 7, 1824-1831.	1.9	46
125	Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e1-e5.	0.8	15
126	Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e13-e18.	0.8	64

#	Article	IF	Citations
127	How I treat von Willebrand disease. Blood, 2009, 114, 1158-1165.	0.6	79
128	Smoking in arterial and venous thrombosis: The missing link?. American Journal of Hematology, 2008, 83, 92-92.	2.0	1
129	The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A. Journal of Thrombosis and Haemostasis, 2008, 6, 494-498.	1.9	38
130	Association or causation: the Janus face of observational research. Journal of Thrombosis and Haemostasis, 2008, 6, 555-557.	1.9	0
131	Bleeding scores in inherited bleeding disorders: clinical or research tools?. Haemophilia, 2008, 14, 415-422.	1.0	76
132	Relevance of quantitative assessment of bleeding in haemorrhagic disorders. Haemophilia, 2008, 14, 68-75.	1.0	13
133	Parallel line bioassay in a coagulation laboratory. A program for personal computer use and an example application to Ristocetin Cofactor assay. International Journal of Laboratory Hematology, 2008, 13, 371-377.	0.2	1
134	Carotid Intima Media Thickness and Plaques Can Predict the Occurrence of Ischemic Cerebrovascular Events. Stroke, 2008, 39, 2470-2476.	1.0	118
135	Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood, 2008, 111, 3998-4003.	0.6	71
136	Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood, 2008, 111, 666-671.	0.6	106
137	Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood, 2008, 111, 3531-3539.	0.6	187
138	Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. Haematologica, 2008, 93, 900-907.	1.7	30
139	D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the prolong extension study. Thrombosis and Haemostasis, 2008, 100, 718-721.	1.8	7
140	A Prospective Evaluation of Bleeding Tendency and Efficacy of Antihemorrhagic Treatments in Patients with Increased Von Willebrand Factor (VWF) Clearance (Von Willebrand Disease Vicenza AND C1130F) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	2
141	Associations of Plasma Fibrinogen Levels with Established Cardiovascular Disease Risk Factors, Inflammatory Markers, and Other Characteristics: Individual Participant Meta-Analysis of 154,211 Adults in 31 Prospective Studies: The Fibrinogen Studies Collaboration. American Journal of Epidemiology, 2007, 166, 867-879.	1.6	199
142	Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease. Haematologica, 2007, 92, 712-713.	1.7	33
143	Association of protein S p.Pro667Pro dimorphism with plasma protein S levels in normal individuals and patients with inherited protein S deficiency. Thrombosis Research, 2007, 120, 421-426.	0.8	9
144	Assessing bleeding in von Willebrand disease with bleeding score. Blood Reviews, 2007, 21, 89-97.	2.8	66

#	Article	IF	Citations
145	Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia. Leukemia, 2007, 21, 1092-1093.	3.3	27
146	Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). Journal of Thrombosis and Haemostasis, 2007, 5, 715-721.	1.9	54
147	How to estimate bleeding risk in mild bleeding disorders. Journal of Thrombosis and Haemostasis, 2007, 5, 157-166.	1.9	75
148	The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. European Journal of Epidemiology, 2007, 22, 839-869.	2.5	153
149	Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics. Internal and Emergency Medicine, 2007, 2, 280-284.	1.0	7
150	d-Dimer Testing to Determine the Duration of Anticoagulation Therapy. New England Journal of Medicine, 2006, 355, 1780-1789.	13.9	593
151	A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). Journal of Thrombosis and Haemostasis, 2006, 4, 766-773.	1.9	478
152	Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. Journal of Thrombosis and Haemostasis, 2006, 4, 2164-2169.	1.9	60
153	Enoxaparin vs. nadroparin for venous thromboembolism prevention: too close to tell?. Journal of Thrombosis and Haemostasis, 2006, 4, 1691-1692.	1.9	2
154	Prothrombin A19911G polymorphism and the risk of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2006, 4, 2582-2586.	1.9	30
155	Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. American Journal of Hematology, 2006, 81, 426-431.	2.0	59
156	Cognitive Impairment and Carotid Atherosclerosis in a General Italian Midlife and Old Population. Neuroepidemiology, 2006, 27, 33-38.	1.1	4
157	Thrombotic and Hemorrhagic Complications after Surgery in Patients with Essential Thrombocythemia and Polycythemia Vera.. Blood, 2006, 108, 2693-2693.	0.6	1
158	Bbeta 14 ArgCys variant dysfibrinogen and its association with thrombosis. Journal of Thrombosis and Haemostasis, 2005, 3, 409-410.	1.9	11
159	Age-adjusted reference limits for carotid intima-media thickness as better indicator of vascular risk: population-based estimates from the VITA project. Journal of Thrombosis and Haemostasis, 2005, 3, 1224-1230.	1.9	43
160	The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. Journal of Thrombosis and Haemostasis, 2005, 3, 2619-2626.	1.9	317
161	Plasma Fibrinogen Level and the Risk of Major Cardiovascular Diseases and Nonvascular Mortality. JAMA - Journal of the American Medical Association, 2005, 294, 1799-809.	3.8	925
162	Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation. Clinical Chemistry and Laboratory Medicine, 2005, 43, 862-8.	1.4	3

#	Article	IF	Citations
163	Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 9-17.	3.1	48
164	Intraindividual consistency of the activated protein C resistance phenotype. British Journal of Haematology, 2004, 126, 405-409.	1.2	11
165	Prevalence and risk factors of non-fatal venous thromboembolism in the active population of the VITA Project. Journal of Thrombosis and Haemostasis, 2003, 1, 1724-1729.	1.9	50
166	The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis. Annals of Internal Medicine, 2003, 139, 470.	2.0	65
167	The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica, 2003, 88, 1182-9.	1.7	31
168	Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2002, 71, 1-6.	2.0	78
169	Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis. Lancet, The, 2001, 357, 441.	6.3	197
170	Phenotypic APC Resistance in Carriers of the A20210 Prothrombin Mutation Is Associated with an Increased Risk of Venous Thrombosis. Thrombosis and Haemostasis, 2001, 86, 804-808.	1.8	20
171	Pulmonary embolism after pregnancy in a patient with polycythemia vera. American Journal of Hematology, 2001, 67, 216-217.	2.0	13
172	Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis. Thrombosis and Haemostasis, 2001, 86, 804-8.	1.8	3
173	Two families with combined homozygous/heterozygous factor V Leiden mutation and heterozygous G20210A factor II variant. Blood Coagulation and Fibrinolysis, 2000, 11, 783-784.	0.5	1
174	The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency. Blood Coagulation and Fibrinolysis, 2000, 11, 321-326.	0.5	8
175	Heterogeneity of Activated Protein C Resistance Phenotype in Subjects with Compound Heterozygosity for HR2 Haplotype and FV Leiden Mutation (R506Q) in Factor V Gene. Thrombosis and Haemostasis, 2000, 84, 357-358.	1.8	18
176	The VITA Project: Heritability of Resistance to Activated Protein C. Thrombosis and Haemostasis, 2000, 84, 811-814.	1.8	16
177	Risk Factors for Thromboembolism. Annals of Internal Medicine, 1999, 131, 790-791.	2.0	0
178	The VITA Project: Prothrombin G20210A Mutation and Venous Thromboembolism in the General Population. Thrombosis and Haemostasis, 1999, 82, 1395-1398.	1.8	41
179	Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis. British Journal of Haematology, 1999, 106, 232-236.	1.2	11
180	The management of 'low-risk' and 'intermediate-risk' patients with primary thrombocythaemia. British Journal of Haematology, 1999, 106, 833-834.	1.2	11

#	Article	IF	Citations
181	The management of â€˜low-riskâ€™ and â€˜intermediate-riskâ€™ patients with primary thrombocythaemia. British Journal of Haematology, 1999, 106, 834-834.	1.2	1
182	Activated Protein C Resistance and Factor V Leiden Mutation Are Independent Risk Factors for Venous Thromboembolism. Annals of Internal Medicine, 1999, 130, 643.	2.0	199
183	The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thrombosis and Haemostasis, 1999, 82, 1395-8.	1.8	5
184	Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation. , 1998, 57, 344-347.		7
185	No treatment for low-risk thrombocythaemia:results from a prospective study. British Journal of Haematology, 1998, 103, 772-777.	1.2	138
186	Additional genetic risk factors for venous thromboembolismin carriers of the factor V Leiden mutation. British Journal of Haematology, 1998, 103, 871-876.	1.2	60
187	Low prevalence of thrombophilia coagulation defects in patients with deep vein thrombosis of the upper limbs. Blood Coagulation and Fibrinolysis, 1997, 8, 191-194.	0.5	37
188	Inherited abnormalities of blood coagulation in juvenile stroke. A case-control study. Blood Coagulation and Fibrinolysis, 1997, 8, 397-402.	0.5	18
189	The VITA Project: C677T mutation in the methyleneâ€tetrahydrofolate reductase gene and risk of venous thromboembolism. British Journal of Haematology, 1997, 97, 804-806.	1.2	87
190	Influence of Cholesterol, Triglycerides and Fibrinogen on AT III, PC, HC-II and Plasminogen Measurement. Thrombosis and Haemostasis, 1997, 77, 804-804.	1.8	2
191	The Epidemiology of Inherited Thrombophilia: the VITA Project. Thrombosis and Haemostasis, 1997, 78, 636-640.	1.8	52
192	The VITA Project: Phenotypic Resistance to Activated Protein C and FV Leiden Mutation in the General Population. Thrombosis and Haemostasis, 1997, 78, 859-863.	1.8	34
193	The epidemiology of inherited thrombophilia: the VITA Project. Vicenza Thrombophilia and Atherosclerosis Project. Thrombosis and Haemostasis, 1997, 78, 636-40.	1.8	9
194	Gestational thrombocytopenia: a prospective study. Haematologica, 1997, 82, 341-2.	1.7	15
195	The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis. Thrombosis and Haemostasis, 1997, 78, 859-63.	1.8	5
196	Factor V Gene Mutation Is a Risk Factor for Cerebral Venous Thrombosis. Thrombosis and Haemostasis, 1996, 75, 393-394.	1.8	136
197	The VITA Project: Population-based Distributions of Protein C, Antithrombin III, Heparin-cofactor II and Plasminogen -Relationship with Physiological Variables and Establishment of Reference Ranges. Thrombosis and Haemostasis, 1996, 76, 226-233.	1.8	49
198	Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. Blood, 1996, 87, 2769-2774.	0.6	51

#	Article	IF	Citations
199	The Ser460Pro substitution of the protein S (PS) gene in rare in Italian patients with type IIa PS deficiency [letter]. Blood, 1996, 88, 3666-3667.	0.6	4
200	Validated Questionnaire for the Identification of Previous Personal or Familial Venous Thromboembolism. American Journal of Epidemiology, 1996, 143, 1257-1265.	1.6	142
201	Thrombosis in Patients with Heterozygous and Homozygous Factor XII Deficiency Is not Explained by the Associated Presence of Factor V Leiden. Thrombosis and Haemostasis, 1996, 76, 275-275.	1.8	5
202	Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thrombosis and Haemostasis, 1996, 75, 393-4.	1.8	34
203	The VITA Project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen--relationship with physiological variables and establishment of reference ranges. Thrombosis and Haemostasis, 1996, 76, 226-33.	1.8	7
204	Family History And Inherited Thrombophilia. British Journal of Haematology, 1995, 89, 227-228.	1.2	7
205	An acquired hemorrhagic disorder of fibrin crosslinking due to LgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. American Journal of Hematology, 1995, 48, 34-39.	2.0	28
206	Platelet von willebrand factor abnormalities in myeloproliferative syndromes. American Journal of Hematology, 1995, 49, 289-293.	2.0	39
207	Diagnosis of APC Resistance in Patients on Oral Anticoagulant Therapy. Thrombosis and Haemostasis, 1995, 73, 732-733.	1.8	24
208	Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thrombosis and Haemostasis, 1995, 73, 732-3.	1.8	3
209	Parallel line bioassay or single-point calibration for the establishment of reference ranges. Thrombosis Research, 1994, 75, 479-483.	0.8	1
210	Preliminary characterization of a new congenital hypodysfibrinogenemia (vicenza II) and of dysfibrinogenemia genova IV. Thrombosis Research, 1993, 70, S119.	0.8	0
211	Some Remarks on the Epidemiology of Thrombotic Disorders. Thrombosis and Haemostasis, 1993, 69, 527-528.	1.8	6
212	The bleeding time in normal subjects is mainly determined by platelet von Willebrand factor and is independent from blood group. Thrombosis Research, 1992, 65, 605-615.	0.8	30
213	Fibrin glue from single-donation autologous plasmapheresis. Transfusion, 1992, 32, 641-643.	0.8	14
214	Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate. American Journal of Hematology, 1992, 41, 132-136.	2.0	42
215	Thrombosis in Subjects with Homozygous and Heterozygous Factor XII Deficiency. Thrombosis and Haemostasis, 1992, 67, 590-590.	1.8	14
216	Thrombosis in subjects with homozygous and heterozygous factor XII deficiency. Thrombosis and Haemostasis, 1992, 67, 590-1.	1.8	2

#	Article	IF	Citations
217	Clinical pharmacokinetics of a placenta-derived factor XIII concentrate in type I and type II factor XIII deficiency. American Journal of Hematology, 1991, 36, 30-34.	2.0	31
218	FACTOR XIII SUBUNIT B DEFICIENCY. British Journal of Haematology, 1990, 76, 317-317.	1.2	2
219	Platelet von Willebrand factor assay: results using two methods for platelet lysis. Thrombosis Research, 1990, 59, 259-267.	0.8	27
220	Von Willebrand Factor Antigen Is Less Sensitive than Ristocetin Cofactor for the Diagnosis of Type I von Willebrand Disease -Results Based on an Epidemiological Investigation. Thrombosis and Haemostasis, 1990, 64, 349-352.	1.8	36
221	von Willebrand factor antigen is less sensitive than ristocetin cofactor for the diagnosis of type I von Willebrand disease--results based on an epidemiological investigation. Thrombosis and Haemostasis, 1990, 64, 349-52.	1.8	3
222	Triton X contaminating platelet lysate critically affects the measurement of von Willebrand factor ristocetin cofactor activity. Thrombosis Research, 1989, 55, 521-526.	0.8	4
223	Von Willebrand Disease. , 0, , 51-61.		3